Menu

Another Genetic Cause of Venous Malformations Found

Mutations in a cancer gene could account for some cases of disfiguring blood vessel abnormalities, scientists show.

Mar 31, 2016
Catherine Offord

Mutations in the PIK3CA gene are linked to venous malformations in the lip, tongue, and hand.SCIENCE TRANSLATIONAL MEDICINE, S. CASTILLO ET AL. (VIA EUREKALERT)Congenital defects in normal blood vessel growth can cause disfiguring lesions called venous malformations (VM) that affect around 1 in 5,000 people. The principal cause of these lesions—mutations in the TEK gene—only accounts for about 50 percent of cases, leaving the remainder largely unexplained. Recently, while studying PIK3CA, a cancer gene coding for a protein involved in cell growth and proliferation, a team led by researchers at University College London discovered a role for this gene in causing VM in mice and humans. The team’s findings were published yesterday (March 30) in Science Translational Medicine.

“We originally set out to investigate cancer by inducing PIK3CA mutations in mice, with no idea that they might be linked to other diseases,” study coauthor Bart Vanhaesebroeck of the University College London Cancer Institute explained in a statement. “It is incredibly exciting to have stumbled across new treatment options for these blood vessel disorders, essentially by accident.”

After engineering mice with mutations in the PIK3CA gene, the researchers quickly noticed the growth of swollen and deformed blood vessels in the animals. When they analyzed VM in human patients using deep sequencing, the researchers also found that PIK3CA mutations were present in around half of the cases in which TEK mutations were absent.

The findings support “the theory that blood vessels are much more sensitive to PIK3CA than other cells,” study coauthor Mariona Graupera of the Bellvitge Biomedical Research Institute in Barcelona said in the statement. “We have previously looked at what happens when PIK3CA is inactivated, but here we saw that an activating mutation in this gene can lead to a dramatic overgrowth of blood vessels.”

The researchers also showed that a drug called rapamycin, which blocks signaling by the PIK3CA protein, reduced the development of VM in mice. However, they noted, rapamycin is unlikely to make a good treatment option for humans. “In patients it can have serious side-effects and compromise the immune system,” study coauthor Sandra Castillo of University College explained in the statement, adding that drugs that directly inhibit PIK3CA could provide a viable alternative.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing